tetano
Editor, Senior Moderator
Nat Immunol
. 2022 Jan 13.
doi: 10.1038/s41590-021-01113-x. Online ahead of print.
Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection
Chansavath Phetsouphanh[SUP] #[/SUP][SUP] 1 [/SUP], David R Darley[SUP] #[/SUP][SUP] 2 [/SUP], Daniel B Wilson[SUP] 3 [/SUP], Annett Howe[SUP] 4 [/SUP], C Mee Ling Munier[SUP] 4 [/SUP], Sheila K Patel[SUP] 5 [/SUP], Jennifer A Juno[SUP] 6 [/SUP], Louise M Burrell[SUP] 5 [/SUP], Stephen J Kent[SUP] 6 7 [/SUP], Gregory J Dore[SUP] 4 2 [/SUP], Anthony D Kelleher[SUP] #[/SUP][SUP] 8 9 [/SUP], Gail V Matthews[SUP] #[/SUP][SUP] 10 11 [/SUP]
Affiliations
Abstract
A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we studied individuals with LC compared to age- and gender-matched recovered individuals without LC, unexposed donors and individuals infected with other coronaviruses. Patients with LC had highly activated innate immune cells, lacked naive T and B cells and showed elevated expression of type I IFN (IFN-β) and type III IFN (IFN-λ1) that remained persistently high at 8 months after infection. Using a log-linear classification model, we defined an optimal set of analytes that had the strongest association with LC among the 28 analytes measured. Combinations of the inflammatory mediators IFN-β, PTX3, IFN-γ, IFN-λ2/3 and IL-6 associated with LC with 78.5-81.6% accuracy. This work defines immunological parameters associated with LC and suggests future opportunities for prevention and treatment.
. 2022 Jan 13.
doi: 10.1038/s41590-021-01113-x. Online ahead of print.
Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection
Chansavath Phetsouphanh[SUP] #[/SUP][SUP] 1 [/SUP], David R Darley[SUP] #[/SUP][SUP] 2 [/SUP], Daniel B Wilson[SUP] 3 [/SUP], Annett Howe[SUP] 4 [/SUP], C Mee Ling Munier[SUP] 4 [/SUP], Sheila K Patel[SUP] 5 [/SUP], Jennifer A Juno[SUP] 6 [/SUP], Louise M Burrell[SUP] 5 [/SUP], Stephen J Kent[SUP] 6 7 [/SUP], Gregory J Dore[SUP] 4 2 [/SUP], Anthony D Kelleher[SUP] #[/SUP][SUP] 8 9 [/SUP], Gail V Matthews[SUP] #[/SUP][SUP] 10 11 [/SUP]
Affiliations
- PMID: 35027728
- DOI: 10.1038/s41590-021-01113-x
Abstract
A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we studied individuals with LC compared to age- and gender-matched recovered individuals without LC, unexposed donors and individuals infected with other coronaviruses. Patients with LC had highly activated innate immune cells, lacked naive T and B cells and showed elevated expression of type I IFN (IFN-β) and type III IFN (IFN-λ1) that remained persistently high at 8 months after infection. Using a log-linear classification model, we defined an optimal set of analytes that had the strongest association with LC among the 28 analytes measured. Combinations of the inflammatory mediators IFN-β, PTX3, IFN-γ, IFN-λ2/3 and IL-6 associated with LC with 78.5-81.6% accuracy. This work defines immunological parameters associated with LC and suggests future opportunities for prevention and treatment.
